6 recruiting, 4 completed, 3 not yet recruiting, 2 unknown. 17 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Recruiting 6, Completed 4, Not yet recruiting 3, Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 3 | 4 | Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Immunoglobulin G4-Related Disease: new trials by email Literature Review of Immunoglobulin G4-Related Disease trials Research Report on Immunoglobulin G4-Related Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD Inebilizumab - Immunoglobulin G4-related Disease | Phase 2 | Not yet recruiting | Amgen | 15 | 2026-10-31 | 2026-08-27 |
| Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease Prednisone, tripterygium wilfordii - IgG4 Related Disease | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 74 | 2026-09-01 | 2026-10-16 |
| A Study of IMM0306 in IgG4-Related Disease IMM0306, Placebo - IgG4-Related Disease | Phase 2 / Phase 3 | Not yet recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 125 | 2026-07-01 | 2026-06-02 |
| Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease ACE1831, Lymphodepleting chemotherapy - IgG4 Related Disease | Phase 1 / Phase 2 | Recruiting | Acepodia Biotech, Inc. | 34 | 2026-01-01 | 2026-10-02 |
| A Study of Efgartigimod in Patients With IgG4-Related Disease Efgartigimod - IgG4-related Disease | Phase 2 | Active not recruiting | Stanford University | 5 | 2025-11-12 | 2026-07-23 |
| The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. [18F]AlF-FAPI-74 PET/CT - Fever of Unknown Origin, IgG4 Related Disease | Phase 2 / Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 140 | 2025-09-17 | 2026-04-17 |
| Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease Anti-BCMA-CD19 CAR-T cells - IgG4 Related Disease, B-cell Mediated Autoimmune Disorders | Phase 2 | Recruiting | Chinese PLA General Hospital | 9 | 2025-09-05 | 2025-09-03 |
| A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy - IgG4 Related Disease | Phase 2 / Phase 3 | Recruiting | Peking Union Medical College Hospital | 198 | 2025-07-07 | 2025-12-30 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Zanubrutinib in Patients With IgG4-Related Disease Zanubrutinib 80 MG - IgG4 Related Disease | Phase 2 | Completed | Matthew C. Baker | 10 | 2022-08-01 | 2026-04-01 |
| Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) elotuzumab, placebo for elotuzumab, methylprednisolone - IgG4 Related Disease, IgG4-RD | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2021-10-13 | 2026-02-05 |
| Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants rilzabrutinib, Glucocorticoids - Immunoglobulin G4 Related Disease | Phase 2 | Completed | Principia Biopharma, a Sanofi Company | 27 | 2020-08-22 | 2025-10-14 |
| Safety and Efficacy of Abatacept in IgG4-Related Disease Abatacept - IgG4-related Disease | Phase 2 | Completed | Massachusetts General Hospital | 10 | 2018-11-13 | 2021-08-24 |
| Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) XmAb5871 - IgG4-RD | Phase 2 | Completed | Xencor, Inc. | 20 | 2016-03-01 | 2018-12-07 |
| Study of Treatment Response on IgG4 Related Disease (IgG4RD) Prednisone, Prednisone and Mycophenolate mofetil - Autoimmune Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2015-04-01 | 2017-01-24 |
| Glucocorticoids in Patients With IgG4-RD Prednisone - IgG4-related Disease | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 40 | 2012-12-01 | 2013-01-01 |
Behcet Syndrome (2) · Myositis (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1) · Autoimmune Diseases (1) · Fever of Unknown Origin (1) · Lupus Erythematosus, Systemic (1) · Purpura, Thrombotic Thrombocytopenic (1) · Recurrence (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
Immune System Diseases (17) · Autoimmune Diseases (16) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases (2) · Genetic Diseases, Inborn (2) · Hereditary Autoinflammatory Diseases (2) · Mouth Diseases (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Panuveitis (2) · Pathologic Processes (2)
Prednisone (4) · Abatacept (1) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Diphenhydramine (1) · Famotidine (1) · GLPG0634 (1) · Glucocorticoids (1) · Histamine H2 Antagonists (1) · Lenalidomide (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · Prednisolone (1) · Saline Solution (1)
Peking Union Medical College Hospital (4) · Acepodia Biotech, Inc. (1) · Amgen (1) · Chinese PLA General Hospital (1) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) · Massachusetts General Hospital (1) · Matthew C. Baker (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Peking University People's Hospital (1) · Principia Biopharma, a Sanofi Company (1) · Stanford University (1) · UMC Utrecht (1) · Universitaire Ziekenhuizen KU Leuven (1) · Xencor, Inc. (1)
China (8) · United States (8) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Greece (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Turkey (Türkiye) (1)
Fengchun Zhang (1) · Jaap M van Laar, Prof. dr. (1) · John H Stone, MD (1) · John H. Stone, MD, MPH (1) · John Stone, M.D., M.P.H. (1) · Matthew C Baker, MD, MS (1) · Wen Zhang, MD (1) · Wen Zhang, Professor (1) · Zhanguo Li (1)
PMID 30124952, PMID 35333600, PMID 38216319, PMID 38251576, PMID 38602546, PMID 38643278, PMID 39672025, PMID 39915014
2025 (1), UM1AI144298 (1)